Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case

Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication associated with poor prognosis and limited treatment options. Emerging T-cell directing therapies, such as bispecific antibodies (bsAbs) and chimeric antigen receptor T cells (CAR-T), have shown remarkable success in treating MM, but their efficacy in CNS involvement remains unclear. Elranatamab, a humanized bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3-expressing T cells, has demonstrated promising results in relapsed refractory MM. However, its efficacy in treating CNS-MM has not been reported. We present a case of a 37-year-old male MM patient with CNS involvement who has been successfully treated with Elranatamab.

Automated summary

Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication, and there are limited treatment options available. Emerging T-cell directing therapies, such as bispecific antibodies (bsAbs) and chimeric antigen receptor T cells (CAR-T), have shown success in treating MM, but their efficacy in treating CNS involvement is still uncertain. This case presents a successful treatment of CNS-involved MM using Elranatamab, a humanized bispecific antibody.